Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating) – Equities research analysts at Jefferies Financial Group lifted their FY2022 EPS estimates for Vanda Pharmaceuticals in a research note issued to investors on Monday, August 29th. Jefferies Financial Group analyst C. Howerton now forecasts that the biopharmaceutical company will post earnings of $0.22 per share for the year, up from their prior estimate of $0.18. The consensus estimate for Vanda Pharmaceuticals' current full-year earnings is $0.18 per share. Jefferies Financial Group also issued estimates for Vanda Pharmaceuticals' FY2023 earnings at $0.29 EPS, FY2024 earnings at $0.39 EPS, FY2025 earnings at $0.48 EPS and FY2026 earnings at $0.75 EPS.

Separately, StockNews.com raised shares of Vanda Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Friday, June 3rd.

Vanda Pharmaceuticals Trading Down 4.0 %

Institutional Investors Weigh In On Vanda Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in VNDA. Wedge Capital Management L L P NC increased its stake in Vanda Pharmaceuticals by 8.8% during the 2nd quarter. Wedge Capital Management L L P NC now owns 11,206 shares of the biopharmaceutical company's stock worth $122,000 after buying an additional 902 shares during the period. Ziegler Capital Management LLC increased its stake in Vanda Pharmaceuticals by 2.6% during the 2nd quarter. Ziegler Capital Management LLC now owns 39,454 shares of the biopharmaceutical company's stock worth $430,000 after buying an additional 1,016 shares during the period. Texas Permanent School Fund increased its stake in Vanda Pharmaceuticals by 2.8% during the 2nd quarter. Texas Permanent School Fund now owns 40,591 shares of the biopharmaceutical company's stock worth $442,000 after buying an additional 1,094 shares during the period. Comerica Bank increased its stake in Vanda Pharmaceuticals by 2.5% during the 1st quarter. Comerica Bank now owns 47,706 shares of the biopharmaceutical company's stock worth $537,000 after buying an additional 1,180 shares during the period. Finally, Yousif Capital Management LLC increased its stake in Vanda Pharmaceuticals by 2.4% during the 1st quarter. Yousif Capital Management LLC now owns 50,710 shares of the biopharmaceutical company's stock worth $574,000 after buying an additional 1,180 shares during the period. 99.42% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 2,700 shares of Vanda Pharmaceuticals stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $9.48, for a total transaction of $25,596.00. Following the transaction, the director now directly owns 6,515 shares of the company's stock, valued at $61,762.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CMO Joakim Wijkstrom sold 3,605 shares of the business's stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $10.27, for a total value of $37,023.35. Following the sale, the chief marketing officer now directly owns 96,673 shares of the company's stock, valued at approximately $992,831.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephen Ray Mitchell sold 2,700 shares of the business's stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $9.48, for a total transaction of $25,596.00. Following the completion of the sale, the director now directly owns 6,515 shares in the company, valued at $61,762.20. The disclosure for this sale can be found here. Insiders have sold 8,544 shares of company stock valued at $87,181 over the last ninety days. Company insiders own 7.00% of the company's stock.

Vanda Pharmaceuticals Company Profile

(Get Rating)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

See Also

• Get a free copy of the StockNews.com research report on Vanda Pharmaceuticals (VNDA)
• Could Snap Stock Rebound As Management Restructures?
• MarketBeat: Week in Review 8/29 – 9/2
• Hormel Looks Cheap At These Levels
• Lululemon Set To Soar Into September
• Could Nike Stock be Oversold, but Still Overvalued?

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.